LAB — Standard Biotools Cashflow Statement
0.000.00%
Last trade - 00:00- $384.06m
- $196.79m
- $85.33m
Annual cashflow statement for Standard Biotools, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -59.2 | -190 | -74.7 | -139 | -74.9 |
| Depreciation | |||||
| Amortisation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 19.5 | 101 | 14.4 | 7.77 | 34.6 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -19.9 | -15.5 | 1.79 | -29.2 | -6.88 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -44.1 | -89.4 | -43.3 | -143 | -74.3 |
| Capital Expenditures | -13.3 | -3.83 | -2.83 | -8.36 | -8.3 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 1.32 | -84.3 | 23.1 | 372 | 35.7 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -11.9 | -88.1 | 20.2 | 363 | 27.4 |
| Financing Cash Flow Items | -1.87 | -12.8 | -0.139 | -1 | -0.484 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 16 | 231 | -6.81 | -103 | 0.57 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -40.1 | 52.9 | -29.8 | 116 | -45.5 |